title: Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.
abstract: OBJECTIVE
  Expression of the genes ERG (v-ets erythroblastosis virus E26 oncogene homolog) and BAALC (brain and acute leukemia, cytoplasmic) shows similarity during hematopoietic maturation and predicts outcome in acute myeloid leukemia. We hypothesized that like ERG, BAALC expression might be of prognostic significance in acute T-lymphoblastic leukemia (T-ALL) and that ERG and BAALC expression together would better identify the patient's risk profile.
  
  
  METHODS
  ERG and BAALC mRNA expression were determined by real-time reverse transcriptase polymerase chain reaction in 153 adults with T-ALL. Patients were designated low or high ERG expressers and low or high BAALC expressers.
  
  
  RESULTS
  High BAALC expression correlated with a higher frequency of early T-ALL (P < .0001), CD34 positivity (P < .0001), coexpression of myeloid markers (P = .0001), and high ERG expression (P = .03). High BAALC compared with low BAALC patients had an inferior relapse-free survival (RFS; P = .0008) and overall survival (OS; P = .0001). In contrast, patients with low expression of both ERG and BAALC (representing 41% of all T-ALL patients) had the most favorable outcome (P < .0001; 4-year RFS: low ERG/low BAALC 81%; P < .0001; 4-year OS: low ERG/low BAALC 69%). On multivariable analysis, low ERG/low BAALC expression was of independent favorable prognostic significance (RFS, P = .001; OS, P = .003).
  
  
  CONCLUSIONS
  Low expression of both ERG and BAALC identifies T-ALL patients with a distinctly favorable long-term outcome.
authors.affiliation: Department of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany. claudia.baldus@charite.de
authors.forename: Claudia D
authors.initials: CD
authors.lastname: Baldus
authors.forename: Peter
authors.initials: P
authors.lastname: Martus
authors.forename: Thomas
authors.initials: T
authors.lastname: Burmeister
authors.forename: Stefan
authors.initials: S
authors.lastname: Schwartz
authors.forename: Nicola
authors.initials: N
authors.lastname: Gökbuget
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
authors.forename: Dieter
authors.initials: D
authors.lastname: Hoelzer
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
authors.forename: Wolf K
authors.initials: WK
authors.lastname: Hofmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D015609:Organotechnetium Compounds; D010091:Oximes; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000401:mortality; D015996:Survival Rate; D015534:Trans-Activators / Q000235:genetics*; D000071230:Transcriptional Regulator ERG
chemical_list: C442828:BAALC protein, human; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D009363:Neoplasm Proteins; D015609:Organotechnetium Compounds; D010091:Oximes; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; C105527:technetium Tc 99m 4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime